D.A. Davidson & CO. Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

D.A. Davidson & CO. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 97,094 shares of the biopharmaceutical company’s stock after acquiring an additional 917 shares during the quarter. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $7,866,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GILD. Tompkins Financial Corp grew its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Private Wealth Management Group LLC purchased a new position in Gilead Sciences in the fourth quarter worth $29,000. Fortitude Family Office LLC purchased a new position in Gilead Sciences in the fourth quarter worth $29,000. Sachetta LLC purchased a new position in Gilead Sciences in the fourth quarter worth $30,000. Finally, Rakuten Securities Inc. purchased a new position in Gilead Sciences in the fourth quarter worth $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. TD Cowen cut their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. Finally, Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a report on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Trading Up 0.1 %

Shares of Gilead Sciences stock opened at $67.35 on Wednesday. The firm has a 50-day simple moving average of $68.93 and a two-hundred day simple moving average of $74.75. The company has a market cap of $83.91 billion, a P/E ratio of 186.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. Gilead Sciences, Inc. has a fifty-two week low of $64.33 and a fifty-two week high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.37 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.57%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.